Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model-Reference-Cited by-同舟云学术

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model

Published:2023-04 Issue:4 Volume:18 Page:499-515
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Moghal Nadeem,Li Quan,Stewart Erin L.,Navab Roya,Mikubo Masashi,D’Arcangelo Elisa,Martins-Filho Sebastiao N.,Raghavan Vibha,Pham Nhu-An,Li Ming,Shepherd Frances A.,Liu Geoffrey,Tsao Ming-Sound^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference61 articles.

1. Overview of current systemic management of EGFR-mutant NSCLC;Hsu;Ann Oncol,2018

2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Greenhalgh;Cochrane Database Syst Rev,2021

3. The quest to overcome resistance to EGFR-targeted therapies in cancer;Chong;Nat Med,2013

4. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies;Lim;Cancer Treat Rev,2018

5. Targeted therapies in the treatment of advanced/metastatic NSCLC;Pallis;Eur J Cancer,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

2. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

3. Osimertinib in Stage III EGFR -Mutated NSCLC — Game, Set, Match;New England Journal of Medicine;2024-08-15

4. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14

5. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08